期刊文献+

β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes 被引量:20

β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes
下载PDF
导出
摘要 Type 2 diabetes(T2DM) is characterized by insulin resistance and β-cell dysfunction. Although, in contrast to type 1 diabetes, insulin resistance is assumed to be a major pathophysiological feature of T2 DM, T2 DM never develops unless β-cells fail to compensate insulin resistance. Recent studies have revealed that a deficit of β-cell functional mass is an essential component of the pathophysiology of T2 DM, implying that β-cell deficit is a common feature of both type 1 and type 2 diabetes. β-cell dysfunction is present at the diagnosis of T2 DM and progressively worsens with disease duration. β-cell dysfunction is associated with worseningof glycemic control and treatment failure; thus, it is important to preserve or recover β-cell functional mass in the management of T2 DM. Since β-cell regenerative capacity appears somewhat limited in humans, reducing β-cell workload appears to be the most effective way to preserve β-cell functional mass to date, underpinning the importance of lifestyle modification and weight loss for the treatment and prevention of T2 DM. This review summarizes the current knowledge on β-cell functional mass in T2 DM and discusses the treatment strategy for T2 DM. Type 2 diabetes (T2DM) is characterized by insulinresistance and β-cell dysfunction. Although, in contrastto type 1 diabetes, insulin resistance is assumed to bea major pathophysiological feature of T2DM, T2DMnever develops unless β-cells fail to compensate insulinresistance. Recent studies have revealed that a deficitof β-cell functional mass is an essential componentof the pathophysiology of T2DM, implying that β-celldeficit is a common feature of both type 1 and type 2diabetes. β-cell dysfunction is present at the diagnosisof T2DM and progressively worsens with diseaseduration. β-cell dysfunction is associated with worseningof glycemic control and treatment failure; thus, it isimportant to preserve or recover β-cell functional massin the management of T2DM. Since β-cell regenerativecapacity appears somewhat limited in humans, reducingβ-cell workload appears to be the most effective way topreserve β-cell functional mass to date, underpinningthe importance of lifestyle modification and weight lossfor the treatment and prevention of T2DM. This reviewsummarizes the current knowledge on β-cell functionalmass in T2DM and discusses the treatment strategy forT2DM.
出处 《World Journal of Diabetes》 SCIE CAS 2015年第1期109-124,共16页 世界糖尿病杂志(英文版)(电子版)
关键词 β-cell INSULIN SECRETION Type 2 DIABETES PREVENTION Treatment β-cell Insulin secretion Type 2 diabetes Prevention Treatment
  • 相关文献

参考文献178

  • 1Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd S, DunningT, Hirst M, Hwang C, Magliano D, Patterson C, Scott C, ShawJ, Soltesz G, Usher-Smith J, Whiting D. IDF Diabetes Atlas.IDF diabetes Atlas. 6th ed. Brussels, Belgium: InternationalDiabetes Federation, 2013.
  • 2Haffner SM, Lehto S, R-nnemaa T, Py-r-l- K, Laakso M.Mortality from coronary heart disease in subjects with type 2diabetes and in nondiabetic subjects with and without priormyocardial infarction. N Engl J Med 1998; 339: 229-234 [PMID:9673301 DOI: 10.1056/NEJM199807233390404].
  • 3Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E,Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF,Holme I, Nj-lstad I, Fletcher A, Nilsson P, Lewington S,Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, HuFB, Danesh J. Diabetes mellitus, fasting glucose, and risk ofcause-specific death. N Engl J Med 2011; 364: 829-841 [PMID:21366474 DOI: 10.1056/NEJMoa1008862].
  • 4Defronzo RA. Banting Lecture. From the triumvirate to theominous octet: a new paradigm for the treatment of type 2diabetes mellitus. Diabetes 2009; 58: 773-795 [PMID: 19336687].
  • 5Kahn SE, Cooper ME, Del Prato S. Pathophysiology andtreatment of type 2 diabetes: perspectives on the past, present,and future. Lancet 2014; 383: 1068-1083 [PMID: 24315620 DOI:10.1016/S0140-6736(13)62154-6].
  • 6Bergman RN, Phillips LS, Cobelli C. Physiologic evaluationof factors controlling glucose tolerance in man: measurementof insulin sensitivity and beta-cell glucose sensitivity fromthe response to intravenous glucose. J Clin Invest 1981; 68:1456-1467 [PMID: 7033284 DOI: 10.1172/JCI110398].
  • 7Bergman RN, Ader M, Huecking K, Van Citters G. Accurateassessment of beta-cell function: the hyperbolic correction.Diabetes 2002; 51 Suppl 1: S212-S220 [PMID: 11815482 DOI:10.2337/diabetes.51.2007.S212].
  • 8Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE. Betacellfunction is a major contributor to oral glucose tolerancein high-risk relatives of four ethnic groups in the U.S. Diabetes2002; 51: 2170-2178 [PMID: 12086947].
  • 9DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologicapproach to therapy in patients with newly diagnosed type2 diabetes. Diabetes Care 2013; 36 Suppl 2: S127-S138 [PMID:23882037 DOI: 10.2337/dcS13-2011].
  • 10Ichise M, Harris PE. Imaging of beta-cell mass and function. JNucl Med 2010; 51: 1001-1004 [PMID: 20554742 DOI: 10.2967/jnumed.109.068999].

同被引文献172

引证文献20

二级引证文献93

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部